StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

Equities research analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Friday. The firm set a “hold” rating on the stock.

A number of other brokerages have also weighed in on EKSO. HC Wainwright lifted their target price on shares of Ekso Bionics from $9.25 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Lake Street Capital initiated coverage on Ekso Bionics in a research report on Monday. They set a “buy” rating and a $2.50 price objective on the stock.

Ekso Bionics Stock Up 2.9 %

Shares of NASDAQ:EKSO opened at $1.05 on Friday. The stock has a market capitalization of $19.08 million, a P/E ratio of -1.08 and a beta of 1.49. The stock’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.60. The company has a current ratio of 2.81, a quick ratio of 2.11 and a debt-to-equity ratio of 0.33. Ekso Bionics has a 12-month low of $0.62 and a 12-month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, April 29th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. The firm had revenue of $3.76 million during the quarter, compared to analysts’ expectations of $4.99 million. During the same period in the previous year, the firm earned ($0.33) earnings per share. On average, equities analysts anticipate that Ekso Bionics will post -0.43 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.